Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Total Liabilities (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Total Liabilities readings, the most recent being $7.3 million for Q4 2025.

  • Quarterly Total Liabilities rose 814.47% to $7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, up 814.47% year-over-year, with the annual reading at $7.3 million for FY2025, 814.47% up from the prior year.
  • Total Liabilities hit $7.3 million in Q4 2025 for Drugs Made In America Acquisition, down from $7.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $7.4 million in Q3 2025 and bottomed at $795669.0 in Q4 2024.